2. Signaling Pathways
  3. PI3K/Akt/mTOR
  4. Akt
  5. Akt1 Isoform
  6. Akt1 Inhibitor

Akt1 Inhibitor

Akt1 Inhibitors (11):

Cat. No. Product Name Effect Purity
  • HY-133120A
    INY-03-041 trihydrochloride
    		Inhibitor 99.27%
    INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively.
  • HY-108232
    MK-2206
    		Inhibitor
    MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities.
  • HY-148868A
    Akt1&PKA-IN-2
    		Inhibitor
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively.
  • HY-129119
    Akt1/Akt2-IN-2
    		Inhibitor 98.57%
    Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells.
  • HY-123035
    Gamendazole
    		Inhibitor
    Gamendazole, an indazole carboxylic acid (ICA), is an orally active, selective HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A) inhibitor. Gamendazole binds to the C-terminal nucleotide binding pocket of HSP90 and cause downregulation of clients AKT1 and ERBB2, but stabilizes the HSP90 heterocomplex. Gamendazole specifically inhibits the actin bundling function of EEF1A1, but does not bind to the nucleotide docking pocket nor inhibits the ribosome charging or protein translation functions of EEF1A1. Gamendazole, an antispermatogenic compound with antifertility effects, has the potential for reversible non-hormonal male contraceptive agent research.
  • HY-163577
    Akt1-IN-5
    		Inhibitor
    Akt1-IN-5 (Compound 115) is an Akt1 inhibitor (IC50: <15 nM)
  • HY-15186C
    Ipatasertib tosylate
    		Inhibitor
    Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models.
  • HY-163578
    Akt1-IN-6
    		Inhibitor
    Akt1-IN-6 (Compound 273) is an Akt1 inhibitor (IC50: <15 nM)
  • HY-163579
    Akt1-IN-7
    		Inhibitor
    Akt1-IN-7 (Compound 370) is an Akt1 inhibitor (IC50: <15 nM).
  • HY-161439
    Akt1-IN-4
    		Inhibitor
    Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM.
  • HY-16032
    Akt1-IN-2
    		Inhibitor
    AKT-I-1 is a selective inhibitor of Akt1, with an IC50 of 4.6 µM.